10.03 - Adult CF

The effect of triple therapy cystic fibrosis transmembrane conductance regulator (CFTR) modulation on anxiety in people with cystic fibrosis

Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.2283 O. O’Carroll, C. Mc Keown, J. Bell, T. Nicholson, C. Gallagher, E. Mc Kone

Triple CFTR modulator therapy is associated with improved endocrine pancreatic function in patients with cystic fibrosis

Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.3750 C. Steinack, T. Gaisl, F. Beuschlein, S. Macé Matthew, M. Ernst

Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): final results of a long-term safety study using US CF Foundation Patient Registry and UK CF Patient Registry data

Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.712 C. Kim, S. Tian, R. Zahigian, A. Elbert, S. Charman, S. Carr, D. Nazareth